SCHEMBL9979047

SCHEMBL9979047

CC(C)(C)OC(=O)Nc1cc(B2OC(C)(C)C(C)(C)O2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.48
WDR77 Q9BQA1 1/20 0.48
AAK1 Q2M2I8 2/20 0.47
DGAT1 O75907 1/20 0.41
HIF1A Q16665 3/20 0.41
GSK3B P49841 2/20 0.40
DYRK1A Q13627 1/20 0.40
IGF1R P08069 1/20 0.40
CCR2 P41597 2/20 0.40
ATR Q13535 1/20 0.39
USP30 Q70CQ3 2/20 0.39
BACE1 P56817 1/20 0.39
BACE2 Q9Y5Z0 1/20 0.39
NAMPT P43490 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.36
GSK3A P49840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29393739 1.00 PRMT5 (0.48) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL28749629 0.89 AAK1 (0.40) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL16923787 0.87 JAK2 (0.43) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL20449019 0.85 PRMT5 (0.46) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL20227776 0.84 GSK3B (0.49) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL25698688 0.84 CYP1A2 (0.43) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL860377 0.82 DGAT1 (0.53) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL25698686 0.82 MAP4K1 (0.45) PRMT5WDR77AAK1DGAT1HIF1A
SCHEMBL626853 0.82 L3MBTL1 (0.44) HIF1AGSK3BGSK3A
SCHEMBL477041 0.82 HIF1A (0.42) DGAT1HIF1AGSK3BGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377152-B2 Compounds for degrading alpha-synuclein aggregates and uses thereof APRINOIA THERAPEUTICS LIMITED (CN) 2025-08-05 US disclosed
US-20240316022-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES, INC. 2024-09-26 US disclosed
US-12012466-B2 Peptide macrocycles against Acinetobacter baumannii HOFFMANN-LA ROCHE INC. (US) 2024-06-18 US disclosed
WO-2024108009-A1 DYRK/CLK PROTACS AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2024-05-23 WO disclosed
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION 2024-01-25 US disclosed
EP-3490970-B1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS VECTUS BIOSYSTEMS LTD (AU) 2023-09-13 EP disclosed
EP-4232449-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-08-30 EP disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 US disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 US disclosed
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 EP disclosed
WO-2011149874-A2 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 SCHERING CORPORATION (US) 2011-12-01 WO disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100179154-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-07-15 US disclosed
US-20100179154-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-07-15 US disclosed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 WO disclosed
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS PFIZER INC 2009-11-05 US disclosed
EP-1737459-B1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2009-08-05 EP disclosed
US-7563788-B2 Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents PFIZER INC. (US) 2009-07-21 US disclosed
WO-2009016286-A2 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-02-05 WO disclosed
US-20070191394-A1 Antibacterial agents WARNER-LAMBERT COMPANY LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316022-A1 INDAZOLE COMPOUNDS FGFR1, FGFR3, FGFR2 PRMT5 1541/4885WDR77 2386/4885AAK1 1349/4885
US-12012466-B2 Peptide macrocycles against Acinetobacter baumannii VIP, ARG1, CX3CR1 PRMT5 665/4885WDR77 1709/4885AAK1 913/4885
US-20240025891-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CYP8B1, PAH, INHA PRMT5 4566/4885WDR77 4232/4885AAK1 4379/4885
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF PRMT5 1465/4885WDR77 1547/4885AAK1 230/4885
US-12377152-B2 Compounds for degrading alpha-synuclein aggregates and uses thereof SNCA, PARK7, PRNP PRMT5 2918/4885WDR77 3664/4885AAK1 2524/4885
US-20070191394-A1 Antibacterial agents MRPL21, RPN2, FBL PRMT5 4139/4885WDR77 4019/4885AAK1 4345/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 PRMT5 241/4885WDR77 375/4885AAK1 533/4885
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS DPYD, TYMP, ITPA PRMT5 2180/4885WDR77 3484/4885AAK1 3665/4885
US-20100179154-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CBR3, DHFR, IL4I1 PRMT5 238/4885WDR77 1174/4885AAK1 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.